Background Image
Previous Page  17 / 22 Next Page
Information
Show Menu
Previous Page 17 / 22 Next Page
Page Background

MQA Q4 2014 - 2015

Balanced Scorecard Measures

Data source:

MQA Licensing & Enforcement Information Database System (LEIDS)

This measure is calculated using the inspection end date and the inspection deficiency data. The number of

sterile compounding pharmacy inspections completed without serious deficiencies is divided by the number of

sterile compounding pharmacy inspections completed during the specified timeframe. It is important to make

sure sterile compounding pharmacies are in compliance with Florida Statutes and administrative rules and do

not pose a threat to the health, safety and welfare of the public.

Due to the implementation of USP 797, standards for sterile compounding pharmacies were raised. The Board

of Pharmacy adopted the standards into Florida Administrative Code Rule 64B16-27.797, and the Bureau of

Enforcement adopted the standards into their inspection forms. To ensure compounded sterile drugs entering

and leaving the state are safe and adhere to USP 797 requirements, the following action steps will be carried

out. Monthly conference calls will be conducted with MQA inspectors to monitor how new standards are affecting

pharmacy passage rates, and all new senior pharmacists will undergo “boot camp” training. Annual “boot

camp” refresher training will also be mandatory for all senior pharmacists. In conjunction with the October

2015 Board of Pharmacy meeting, the Bureau of Enforcement will facilitate a meeting to educate pharmacies

and pharmacists on common sterile compounding deficiencies. Pharmacies that have substantive deficiencies

during an inspection must provide a corrective action plan that is reviewed for compliance and a follow-up

inspection will be conducted.

INITIATIVE:

TARGET: 95%

MEASURE:

Percent of sterile compounding pharmacy inspections with no serious deficiencies.

DEFINITION:

16

Sterile Compounding Pharmacy Inspections

89.88

75.68

89.83

83.54

78.53

73.91

% without serious deficiencies

95

90

85

80

75

70

FY 13-14 Q3 FY 13-14 Q4 FY 14-15 Q1

FY 14-15 Q2 FY 14-15 Q3 FY 14-15 Q4

TARGET = 95%

l